Uncategorized
Replimune gets early August decision date for twice-rejected melanoma drug
Replimune gets early August decision date for twice-rejected melanoma drug
Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections. The FDA expects to hold an advisory committee meeting in late July. Read More